NewKerala.com

Lupin's US Plant Gets FDA Form 483 with Three Observations

Pharmaceutical major Lupin has announced that the US Food and Drug Administration (USFDA) issued a Form 483 with three observations following an inspection of its manufacturing facility in Somerset, New Jersey. The company stated it will address the observations and respond to the regulator within the stipulated timeframe. This comes after a similar inspection at Lupin's Ankleshwar plant in India last month also resulted in a Form 483. A Form 483 is issued when investigators observe conditions that may violate US food and drug regulations.

Key Points: Lupin US Facility Receives FDA Form 483 with Observations

  • USFDA inspection at Lupin's New Jersey facility
  • Form 483 issued with three observations
  • Company to address findings within timeline
  • Follows similar inspection in India in March
  • Form 483 indicates potential regulatory violations
2 min read

USFDA issues 'Form 483' with three observations to Lupin US facility

Lupin says USFDA issued a Form 483 with three observations after inspecting its New Jersey plant. The company pledges to address them promptly.

"The inspection was completed with the issuance of a Form 483 carrying three observations. - Lupin"

New Delhi, April 18

Major drug maker Lupin on Saturday said that the US health regulator has issued a 'Form 483' with three observations to its manufacturing facility in Somerset, New Jersey, following a recent inspection.

In a regulatory filing, the pharmaceutical company said that the inspection by the US Food and Drug Administration (USFDA) was conducted this week between April 13 and April 17.

"The inspection was completed with the issuance of a Form 483 carrying three observations," the drug maker said.

The company further added that it will address the observations and respond to the USFDA within the stipulated timeframe.

Lupin also said it remains committed to maintaining compliance with current Good Manufacturing Practices (cGMP) standards across all its facilities.

Earlier in March, the USFDA had concluded an inspection at the company's Ankleshwar manufacturing facility in India -- conducted from March 2 to March 7-- which also resulted in a Form 483 with two observations.

The company had said at the time that it would address the observations and respond within the required timeline, while maintaining compliance with cGMP standards.

According to the USFDA, a Form 483 is issued to a company's management at the end of an inspection when investigators observe conditions that may constitute violations of the Food, Drug and Cosmetic (FD&C) Act and related regulations.

Shares of Lupin on Friday ended at Rs 2,322.50, a decrease of 0.19 per cent, on the NSE. Moreover, the pharma stock has touched a 52-week high of Rs 2,377.60 and a 52-week low of Rs 1,836.80 on the exchange.

- IANS

Share this article:

Reader Comments

S
Sarah B
As someone who works in the industry, a Form 483 with three observations is fairly standard and not a catastrophe. The key is their response and corrective action. Lupin's statement sounds proactive. Let's see what the observations actually are.
A
Ananya R
The stock price dip is minimal, which suggests the market isn't panicking. Investors seem to trust that Lupin will handle this. It's a reminder that compliance is a continuous process, not a one-time achievement.
V
Vikram M
With respect, this points to a potential systemic issue in their quality processes. First Ankleshwar, now New Jersey. The management needs to look beyond just "addressing observations" and ensure robust quality culture across ALL facilities. Patient safety is paramount.
K
Karthik V
USFDA inspections are notoriously strict. The fact that they got only 3 observations, and not a warning letter or import alert, is actually a positive sign in a way. Most plants get observations. Jai Hind, hope they fix it soon!
M
Michael C
The article clearly explains what a Form 483 is—it's an inspection report, not a final judgment. The timeline is important. They have 15 days to respond. Lupin's global reputation depends on how effectively they close this out.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50